Tristetraprolin Regulates Interleukin-6, Which Is Correlated With Tumor Progression in Patients With Head and Neck Squamous Cell Carcinoma

Elizabeth Van Tubergen, DDS1; Robert Vander Broek, BS1; Julia Lee, MPH, MS2; Gregory Wolf, MD3; Thomas Carey, PhD3; Carol Bradford, MD3; Mark Prince, MD3; Keith L. Kirkwood, DDS, PhD4; and Nisha J. D’Silva, BDS, MSD, PhD1,5

BACKGROUND: Tumor-derived cytokines play a significant role in the progression of head and neck squamous cell carcinoma (HNSCC). Targeting proteins, such as tristetraprolin (TTP), that regulate multiple inflammatory cytokines may inhibit the progression of HNSCC. However, TTP’s role in cancer is poorly understood. The goal of the current study was to determine whether TTP regulates inflammatory cytokines in patients with HNSCC. METHODS: TTP messenger RNA (mRNA) and protein expression were determined by quantitative real-time–polymerase chain reaction (Q-RT-PCR) and Western blot analysis, respectively. mRNA stability and cytokine secretion were evaluated by quantitative RT-PCR and enzyme-linked immunoadsorbent assay, respectively, after overexpression or knockdown of TTP in HNSCC. HNSCC tissue microarrays were immunostained for interleukin-6 (IL-6) and TTP. RESULTS: TTP expression in HNSCC cell lines was found to be inversely correlated with the secretion of IL-6, vascular endothelial growth factor (VEGF), and prostaglandin E2 (PGE2). Knockdown of TTP increased mRNA stability and the secretion of cytokines. Conversely, overexpression of TTP in HNSCC cells led to decreased secretion of IL-6, VEGF, and PGE2. Immunohistochemical staining of tissue microarrays for IL-6 demonstrated that staining intensity is prognostic for poor disease-specific survival (P = .023), tumor recurrence and development of second primary tumors (P = .014), and poor overall survival (P = .019). CONCLUSIONS: The results of the current study demonstrated that down-regulation of TTP in HNSCC enhances mRNA stability and promotes secretion of IL-6, VEGF, and PGE2. Furthermore, high IL-6 secretion in HNSCC tissue is a biomarker for poor prognosis. In as much as enhanced cytokine secretion is associated with poor prognosis, TTP may be a therapeutic target to reduce multiple cytokines concurrently in patients with HNSCC. Cancer 2011;117:2677–89. © 2011 American Cancer Society. KEYWORDS: cytokines, interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), prostaglandin E2 (PGE2), messenger RNA (mRNA) stability.
in the 5'- and 3'-untranslated region (UTR) of mRNA transcripts. Because cytokine transcripts contain AREs in their 3'UTR, proteins that promote degradation or stability of transcripts by binding to this region have therapeutic potential.

Expression of RNA-BPs that regulate cytokine mRNA stability may be altered in cancer. In breast cancer, overexpression of human-related antigen R (HuR), an RNA-BP that stabilizes mRNA, contributes to poor prognosis and the increased secretion of VEGF. Conversely, in colon cancer, tristetraprolin (TTP), which decreases mRNA stability, is down-regulated, correlating with increased COX-2 expression. These changes in RNA-BPs underscore their significance in cancer progression.

HNSCC is the sixth most common cancer, annually affecting approximately 500,000 individuals worldwide. The 5-year survival rate is approximately 50%, primarily because of late detection. HNSCCs secrete multiple cytokines including VEGF, IL-6, and COX-2. Because COX-2 and IL-6 inhibitors decrease cell proliferation and invasion in HNSCC in vitro, cancer therapy targeted toward tumor-secreted inflammatory cytokines may inhibit tumor progression. Treating HNSCC with agents directed at a single cytokine is unrealistic because of the secretion of multiple cytokines with overlapping functions. Given the importance of cytokines such as IL-6, PGE₂, tumor necrosis factor-α (TNF-α), VEGF, and epidermal growth factor in HNSCC progression, down-regulation of multiple cytokines simultaneously by targeting a common upstream protein may inhibit HNSCC progression. However, to our knowledge, the role of TTP in the regulation of multiple cytokines has not been investigated in HNSCC. Furthermore, the relation between TTP expression and cytokine secretion in HNSCC progression has not been established. In the current study, we investigated whether TTP regulates multiple inflammatory cytokines in HNSCC and the significance of the overexpression of one of these cytokines on tumor progression.

**MATERIALS AND METHODS**

**Cell Culture**

The human HNSCC cell lines UM-SCC-1, UM-SCC-5, UM-SCC-11A, UM-SCC-14A, UM-SCC-17B, UM-SCC-22B, UM-SCC-74A, and UM-SCC-81B and OSCC3 cells were cultured as described. Primary human oral keratinocytes (NHK) were cultured in oral keratinocyte growth medium (ScienCell, Carlsbad, Calif). Western Blot Analysis

Whole-cell lysates were prepared by sonicating cell suspensions on ice, and Western blot analysis was performed as described. Membranes were blocked and incubated in the primary antibody overnight at 4°C or for 1 hour at room temperature. Antibody concentrations were as follows: rabbit anti-TTP (Abcam, Cambridge, UK) at a dilution of 1:2000, actin (Cell Signaling Technology, Inc, Danvers, Mass) at a dilution of 1:3000, and horseradish peroxidase-conjugated donkey antirabbit immunoglobulin G and goat antimouse secondary antibodies (dilutions of 1:2000 to 1:5000; Jackson ImmunoResearch Laboratories, Inc, West Grove, Pa). Immunoreactive proteins were observed using the SuperSignal West Pico Chemiluminescent Substrate system (Pierce, Rockford, Ill) and exposed to x-ray film.

**Quantitative-Real-Time-Polymerase Chain Reaction**

Total RNA was isolated from cells with QIAzol (Qiagen, Valencia, Calif). Complementary DNA (cDNA) was synthesized using SuperScript II (Invitrogen, Carlsbad, Calif). Quantitative real-time polymerase chain reaction (Q-RT-PCR) was performed with SYBR Green Master Mix on an Applied Biosystems ABI 7500 RealTime PCR System (Applied Biosystems, Foster City, Calif). Data were analyzed using the delta-delta cycle threshold method with normalization to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and then expressed relative to NHK.

**Adenoviral Infection and IL-1β Induction**

A DL3 replication-deficient serotype-5 adenovirus (Ad-5) containing cytomegalovirus (CMV)β-galactosidase (gal) and human TTP were generated through the University of Michigan Vector Core as described. The cell lines...
UM-SCC-11A and UM-SCC-17B and OSCC3 cells (35 x 10^5) were transduced with 1000 multiplicity of infection (MOI) Ad-5-β-gal or Ad-5-TTP in serum-free media. Three hours after transduction, 10% fetal bovine serum (FBS) was added. Twenty-one hours later, HNSCC cell lines were serum starved for 4 hours and incubated with 1 ng/mL of IL-1β or phosphate-buffered saline (PBS) in serum-free media. Conditioned media were collected after 24 hours.

Enzyme-Linked Immunoabsorbent Assay for IL-6, VEGF, and PGE2.
Conditioned medium from NHK, HOK-16B, OSCC3, and HNSCC cell lines (UM-SCC-1, UM-SCC-11A, UM-SCC-14A, UM-SCC-17B, UM-SCC-22B, UM-SCC-74A, and UM-SCC-81B) was processed as described.27 The total cell number was measured with a trypan blue enumeration assay. IL-6 and VEGF secreted into the medium were measured by a noncompetitive enzyme-linked immunoabsorbent assay (ELISA) whereas PGE2 was measured using a competitive ELISA (R&D Systems, Minneapolis, Minn).

Transient TTP Knockdown
The UM-SCC-1, UM-SCC-22B, and UM-SCC-81B cell lines were transfected with ON-TARGET plus TTP (Zfp36) SMART Pool (Dharmacon Inc, Lafayette, Colo) small interfering RNA (siRNA). The UM-SCC-1 cell line was transfected with Nucleofectin (Amaxa Biosystems, Gaithersburg, Md) as described.23,28 The UM-SCC-22B and UM-SCC-81B cell lines (25 x 10^4 in 6 well dishes) were transfected with 1 μg of siRNA using Lipofectamine RNAiMax (Invitrogen), as described.29 Four hours after transfection, 10% FBS was added. Conditioned media and whole-cell lysates were collected as described earlier.

Stable TTP Knockdown and mRNA Decay
For stable knockdown of TTP, the UM-SCC-1 and UM-SCC-22B cell lines were infected with short hairpin RNA (shTTP and sh vesicular stomatitis virus glycoprotein [VSVG] control) in lentiviral particles in a VSVG backbone (University of Michigan Vector Core). Stable cell lines were selected in 10 μg/mL of puromycin (Sigma Chemical Company, St. Louis, Mo). For mRNA decay experiments, 35 x 10^4 cells were plated in 60-mm dishes. The next day, the cells were serum starved for 4 hours and treated with 10 nM of actinomycin D for 0, 1, 2, and 3 hours (Sigma Chemical Company). After incubation, cells were washed with PBS and RNA was harvested.

Invasion Assay
In vitro cell invasion was determined according to the manufacturer’s instructions (BD Biosciences, Franklin Lakes, NJ), as described previously.23,28 Cells were washed and plated on Matrigel-coated inserts at 2.5 to 3.5 x 10^4 cells in Dulbecco modified Eagle medium (DMEM) in triplicate. For control experiments, cells were plated in DMEM on identical inserts that were not coated with Matrigel. The lower chamber contained DMEM with 10% FBS as a chemoattractant. After incubation for 24 hours, cells that had migrated to the lower surface of the membrane were fixed and stained with 10% methanol and crystal violet. To determine the percentage invasion, the average number of cells per field on the invasion inserts was divided by the average number of cells per field on the control inserts and multiplied by 100.

Migration Assay
Cells were plated at 95% density in 24-well plates in triplicate. Twenty-four hours after plating, cells were serum starved for 6 hours, then treated with 25 mM of mitomycin C (Sigma Chemical Company) for 2 hours in serum-free conditions. Media was removed and a scratch was made with a 200-μL pipette tip. Immediately after the scratch, complete media with 25 mmol of mitomycin C was added and 3 fields in each replicate were photographed at 0 hours and at 24 hours. The area between the migration fronts was determined using ImagePro Plus 5.1 (Media Cybernetics Inc, Bethesda, Md) and the percentage migration at 24 hours was calculated.

University of Michigan Oral Cavity/Oropharyngeal Cancer Organ Preservation Trial
This randomized clinical trial of patients with stage III/IV HNSCC (TNM staging system) compared patients treated concurrently with chemotherapy and radiotherapy versus those treated with surgery and radiotherapy after induction chemotherapy.30 A tissue microarray (TMA) constructed from pretreatment specimens from this clinical trial was used for immunohistochemical studies after Institutional Review Board approval.

Immunohistochemistry
Immunodetection in tissue sections was performed as described24 with affinity-purified anti-IL–6 (R&D Systems; 25 μg/mL), affinity-purified TTP antibody (Abcam; 3 μg/mL), or the corresponding IgG controls at the same concentrations.
Statistical Analysis
Statistical analysis of in vitro assays was performed using a Student t test or 1-way analysis of variance (ANOVA). A P value < .05 was considered to be statistically significant. For analysis of TMA data, interpretation and scoring were performed by a board certified pathologist, as described. The covariates of interest were T classification and N classification, which were analyzed as ordinal data. The outcomes of interest were overall survival, disease-specific survival (DSS), time to indication of surgery at the primary tumor site, and time to disease recurrence or the development of second primary tumors. The Spearman correlation coefficient was used to evaluate univariate associations between markers and numerical and ordinal variables of interest. The Cox proportional hazards model was used to relate time-to-event outcomes to marker levels and other numerical and ordinal covariates. Statistical analyses of TMA data were performed using SAS statistical software (version 9.0; SAS Institute Inc, Cary, NC). A 2-tailed P value ≤ .05 was considered to be statistically significant.

RESULTS
TTP Is Down-Regulated in HNSCC
TTP expression was evaluated by quantitative real-time–PCR and normalized to GAPDH. The TTP transcript was lower in 6 HNSCC cell lines compared with NHK (Fig. 1A) (P < .05, Student t test). The UM-SCC-11A and UM-SCC-22B cell lines had significantly more TTP mRNA than NHK (P < .05, Student t test). Whole-cell lysates from 9 HNSCC cell lines and from 2 nonmalignant cell lines NHK and immortalized keratinocytes (HOK-16B, designated as IHOK) were immunoblotted with anti-TTP antibody. As shown in Figure 1B (immunoblot and densitometric analyses), TTP expression was higher in NHK and IHOK compared with HNSCC cell lines when normalized to actin as a loading control.
OSCC3 cells expressed the least amount of TTP compared with NHK (83% reduction), whereas the UM-SCC-81B cell line demonstrated the least reduction in TTP expression compared with NHK. There was an overall decrease in TTP expression of 62% (standard deviation [SD], 24.6%) in HNSCC cell lines compared with NHK.

IL-6, VEGF, and PGE2 were quantified by ELISA in conditioned media from normal and IHOK and HNSCC cells to correlate TTP expression with cytokine secretion. In 7 of the 11 HNSCC cell lines, IL-6 secretion was found to be significantly up-regulated (*indicates \( P < .001 \), 1-way ANOVA for all cell lines noted) in HNSCC cell lines compared with NHK. VEGF and PGE2, the other 2 cytokines evaluated, demonstrated a similar trend. The increase in VEGF secretion was significant in 8 of 9 HNSCC cell lines (*indicates \( P < .001 \), 1-way ANOVA). The increase in PGE2 secretion was significant in 5 of 9 HNSCC cell lines (\( P < .001 \), 1-way ANOVA). Of the cell lines evaluated, NHK secreted the least VEGF and PGE2 (Figs. 1D and 1E, respectively). IHOK demonstrated increased VEGF and PGE2 secretion compared with normal cells, but less than that observed in the HNSCC cell lines. The UM-SCC-81B cell line secreted high levels of all 3 cytokines evaluated, despite high TTP expression in these cell lines (Fig. 1B). However, in the majority of cell lines (>65%), TTP expression was found to be inversely correlated with cytokine secretion.

**Overexpression of TTP Reduces Cytokine Secretion in HNSCC**

Three HNSCC cell lines with approximately 50% reduced endogenous TTP expression compared with NHK (Fig. 1B) were used for overexpression studies. To verify TTP overexpression, whole-cell lysates were generated from HNSCC cell lines transduced with Ad-5 that contained either TTP or \( \beta \)-gal (control) and were immunoblotted for TTP. As shown in Figure 2A, TTP was overexpressed in the UM-SCC-11A cell line UM-SCC-17B cell line, and OSCC3 cells transduced with Ad-5–TTP compared with cells transduced with control vector.

IL-1\( \beta \) is secreted by inflammatory cells adjacent to a tumor and activates the p38 mitogen-activated protein kinase (MAPK) pathway within tumor cells.\(^{31}\) Mitogen-activated protein kinase-activated protein kinase 2 (MK2), the downstream target of p38 MAPK, inactivates TTP by phosphorylation.\(^{32,33}\) Therefore, we investigated the effect of TTP on cytokine secretion in the presence and absence of IL-1\( \beta \). In mock-transduced cells, IL-1\( \beta \) increased cytokine secretion in all 3 cell lines, which is consistent with inactivation of residual TTP. However, overexpression of TTP led to a significant reduction in IL-6, VEGF, and PGE2 secretion in all 3 cell lines (Figs. 2B, 2C, and 2D) (*indicates \( P < .001 \)) when compared with cells transfected with control vector, even in the presence of IL-1\( \beta \).

In a complementary approach, TTP expression was down-regulated by RNA interference (RNAi) in 3 HNSCC cell lines representing a spectrum of TTP expression. Knockdown of TTP, verified by immunoblot analysis, led to increased secretion of IL-6, VEGF, and PGE2 (Fig. 3). In the UM-SCC-1 cell line, small interfering TTP (siTTP) mediated a significant increase in all 3 cytokines evaluated (Fig. 3A) (\( P < .05 \)). IL-6 secretion was increased more than PGE2 secretion in the UM-SCC-22B cell line (\( P < .05 \)). VEGF secretion demonstrated a similar trend (Fig. 3B). In the UM-SCC-81B cell line, which strongly expresses TTP (Fig. 1A), siTTP also induced a significant increase in the secretion of IL-6, VEGF, and PGE2 (Fig. 3C) (\( P < .05 \)). Collectively, overexpression and knockdown data suggest that TTP inversely regulates IL-6, VEGF, and PGE2 secretion in HNSCC.

**TTP Regulates Cytokine mRNA Stability in HNSCC**

To determine whether TTP targets cytokine mRNA for degradation in HNSCC, cells were treated with actinomycin D, which inhibits DNA polymerase. Stable cell lines with shTTP or shSVVG in the UM-SCC-1 and UM-SCC-22B cell lines were generated. Knockdown of TTP, confirmed by immunoblot analysis (Fig. 4A), increased cytokine mRNA stability. For the UM-SCC-1 cell line, mRNA transcripts of IL-6 and COX-2 in shTTP-transduced cells remained between 90% and 100% stable over a 3-hour period. In contrast, in cells transduced with shSVVG, mRNA transcripts degraded to nearly 50% at 3 hours (Fig. 4B) (\( P < .05 \)). Similarly, in the UM-SCC-22B cell line, IL-6 and COX-2 mRNAs were more stable in cells transduced with shTTP (approximately 100% after 3 hours) compared with control (shSVVG) cells, in which IL-6 and COX-2 mRNA were degraded in 3 hours (Fig. 4C) (\( P < .05 \)).

**Loss of TTP Enhances Invasion and Migration**

In HNSCC, invasion and migration facilitate tumor progression. To determine the functional significance of loss of TTP, invasion and migration assays were performed...
with the UM-SCC-1 cell line after shRNA-mediated knockdown of TTP (Fig. 4A). Loss of TTP in the UM-SCC-1 cell line increased invasion nearly 300% compared with control cells transduced with empty vector (Fig. 5A). Migration assays demonstrated that suppression of TTP increases cell migration. In the UM-SCC-1 cell line, the percentage area migrated, normalized to time 0, was 75% in shTTP cells whereas control cells migrated 15% (Fig. 5B). Similar results for invasion and migration were observed in the UM-SCC-22B cell line (data not shown).

Figure 2. Overexpression of tristetraprolin (TTP) in head and neck squamous cell carcinoma (HNSCC) cell lines decreases cytokine secretion. (A) The UM-SCC-11A cell line, (B) UM-SCC-17B cell line, and (C) OSCC3 cells were transduced with serotype-5 adenovirus containing β-galactosidase (β-gal) (control) or TTP. Cell lysates and conditioned media were harvested. Cell lysates were electrophoresed and immunoblotted with TTP antibody. Conditioned media was used to quantify interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), and prostaglandin E2 (PGE2) secretion by enzyme-linked immunoadsorbent assay. All experiments were performed in triplicate (*indicates P < .001). Standard error bars are present in all graphs. + indicates positive; −, negative.
Increased IL-6 Secretion Is Correlated With Human HNSCC Progression

Immunohistochemical studies were performed on normal epithelial and HNSCC tumor tissue and a TMA of pretreatment tissue specimens from HNSCC. Normal epithelial tissue was found to demonstrate strong TTP staining in the basal one-third of the epithelium (Fig. 6A Left, indicated by arrows), whereas the invasive epithelial islands in the HNSCC tissue did not demonstrate strong TTP staining (Fig. 6A Right, inset). IgG controls were found to be negative (data not shown). Figure 6B (Top and Bottom) demonstrates high IL-6 and low TTP staining within the same HNSCC core. IgG controls were appropriately negative (data not shown). Low TTP and high IL-6 intensity were found to be correlated with poor DSS, (*P = .043) (Fig. 6C). In addition, TMA findings revealed that high IL-6 intensity is prognostic for bad patient outcomes, specifically poor DSS (*P = .023) (Fig. 6D), tumor recurrence or the development of a second primary tumor (*P = .014) (Fig. 6E), and poor overall survival (*P = .019) (data not shown). Thus, these findings based on a small sample size indicate that IL-6 and TTP expression are inversely correlated and that IL-6 is associated with poor patient outcome.
DISCUSSION

Changes in oncogenic mRNA stability can alter the production of inflammatory cytokines. For example, up-regulation of HuR, an RNA-BP that stabilizes mRNA, enhances COX-2 and VEGF production. This increase in cytokine production is detrimental because tumor-derived cytokines facilitate oncogenic phenotypes such as invasion, proliferation, and survival, thereby promoting tumor growth. Consistent with this theory, increased COX-2 production in colon cancer increases tumor invasion. The results of the current study demonstrate that down-regulation of TTP in HNSCC stabilizes transcripts and promotes the secretion of multiple cytokines, including IL-6, VEGF, and COX-2, and increases invasion and migration. Furthermore, IL-6 and TTP expression are inversely correlated in human HNSCC tissue. High IL-6 expression is predictive of poor DSS, tumor recurrence, and the development of second primary tumors. On the basis of the findings in this study performed in a small group of patients, patients with HNSCC tumors with high IL-6 staining intensity appear to have a much poorer prognosis than those patients with tumors expressing IL-6 at low levels.

HNSCC is a disease with a poor prognosis, with 5-year survival rates of approximately 50%. HNSCCs secrete multiple growth, inflammatory, and angiogenic factors, including VEGF, IL-6, IL-8, and GM-CSF, which promote tumor progression. IL-6 promotes tumor growth in mice by promoting the survival and proliferation of HNSCC cells. Other cytokines, such as VEGF, promote angiogenesis and metastasis.

The critical role of cytokines in the progression of many cancers makes them an attractive treatment target. In a murine model, IL-6 monoclonal antibodies decreased the size of prostate cancer xenografts significantly. However, targeting individual cytokines is
unlikely to be of therapeutic benefit in humans. For example, results from a clinical trial in patients with multiple myeloma with antibodies against IL-6 indicated that there was no improvement in clinical outcome for these patients.

This suggests that cytokines secreted can compensate for one another and therefore this limits the effect of an inhibitor specific for each cytokine. Targeting a common regulatory mechanism for multiple cytokines such as IL-6, VEGF, and PGE₂ in HNSCC may decrease tumor progression and improve response to treatment.

Cytokine mRNA expression is tightly regulated in resting cells through continuously active mRNA decay mechanisms. Induction of mRNA decay via inflammatory signals facilitates rapid changes in the cellular production of cytokines through alterations in binding of RNA-BP. RNA-BPs regulate multiple cytokines by inducing decay or inhibiting translation. RNA-BPs may bind to multiple AREs, possibly contributing to competition for binding. At least 20 different proteins that can bind to ARE segments have been identified to date, including TTP, HuR, butyrate response factor (BRF)-1 and BRF-2, ARE/poly(U)-binding/degradation factor-1 (AUF-1), T cell intracellular antigen-1 (TIA-1) and T-cell-restricted intraacellular antigen-related protein (TIAR). However, only a subset of RNA-BPs has been shown to influence the stability or translational efficiency of target mRNAs.

One of the most well-studied RNA-BPs is TTP, which targets mRNA for rapid degradation by binding to the AREs in the 3′UTR. Studies with knockout mice suggest that TTP is crucial in regulating TNF-α and IL-6. Because TTP regulates mRNAs of multiple inflammatory cytokines by increasing turnover and inducing decay, loss of TTP may lead to the increased production of multiple cytokines, which may be associated with tumor progression. In some cancers, such as colon cancer, loss of TTP contributes to tumor growth by increasing COX-2, VEGF, or matrix metalloproteinase-1 (MMP-1) production. However, these studies did not evaluate how TTP overexpression influences the production of multiple cytokines. In the current study, we demonstrated that knockdown of TTP in HNSCC stabilizes the transcripts of multiple cytokines and enhances invasion and migration.

Because of the host-tumor microenvironment, inflammatory mediators, such as IL-1β, produced by inflammatory cells that are adjacent to the tumor may activate the p38 MAPK pathway within the tumor cells. Therefore, in the current study, we investigated the effect of TTP on cytokine secretion in the presence or absence of IL-1β. However, TTP overexpression was found to decrease the secretion of cytokines regardless of stimulation with IL-1β. Although the absolute value of the reduction (ie, pg/mL/million cells) was greater with the addition of IL-1β, the fold decrease in cytokine secretion...
Figure 6. Interleukin-6 (IL-6) intensity is prognostic for disease-specific survival and tumor recurrence in patients with head and neck squamous cell carcinoma (HNSCC). (A) Immunohistochemistry was performed on tissue sections of normal human epithelium (Left; bar = 100 μm) and human HNSCC (Right; bar = 1000 μm) with tristetraprolin (TTP) antibody. Arrows indicate staining in the basal one-third of normal epithelium. Inset: Higher magnification of the outlined box demonstrating invasive epithelium is shown (bar = 60 μm). Arrow indicates invasive epithelium. (B) Immunohistochemistry was performed on tissue sections of a human HNSCC tissue microarray with the IL-6 and TTP antibodies. The slides were counterstained with hematoxylin. The top and bottom panels represent high IL-6 and low TTP staining, respectively, in the same HNSCC tissue section (bars = 100 μm). (C) Low TTP and high IL-6 are correlated with poor disease-specific survival. Patient groups are indicated by colored lines. Red line indicates low TTP and low IL-6 (n = 9 patients); yellow line, low TTP and high IL-6 (n = 3 patients); blue line, high TTP and low IL-6 (n = 11 patients); green line, high TTP and high IL-6 (n = 10 patients). Events (indicated by a drop in the graph lines) were deaths from HNSCC. Subjects who did not experience the events, such as patients who died of unrelated causes, were censored. (D and E) High IL-6 intensity is prognostic for (D) poor disease-specific survival and (E) the development of tumor recurrence and second primary tumors. Patient groups are indicated by colored lines. Red line indicates no IL-6 (n = 6 patients); yellow line, low IL-6 (n = 19 patients); blue line, medium IL-6 (n = 14 patients); green line, high IL-6 (n = 3 patients). IL-6 intensity is also prognostic for poor overall survival (data not shown).
after TTP overexpression was greater in unstimulated compared with IL-1β–treated cells, which is consistent with inactivation of part of the overexpressed TTP by IL-1β.

TTP expression was found to be reduced in all HNSCC cell lines compared with NHK. We observed that there was a 62% (SD, 24.6%) reduction in TTP expression in HNSCC compared with NHK. However, reduced TTP expression was not found to correlate 100% with increased cytokine secretion in HNSCC cells, which may be because of phosphorylation-mediated inactivation of TTP. MK2, the downstream target of p38 MAPK, phosphorylates TTP at serine sites 52 and 178 and renders the protein inactive by inducing binding of TTP to 14-3-3 protein.32,33 We observed that TTP expression was inversely correlated with cytokine secretion except for the UM-SCC-81B cell line, which was found to strongly express TTP but secreted high levels of cytokines. This may be the result of TTP phosphorylation because active p38 MAPK, which inactivates TTP by phosphorylation, is up-regulated in HNSCC. We were unable to immunoprecipitate TTP using available antibodies, but p38 MAPK is active in this cell line. Collectively, these data suggest that loss or inactivation of TTP contributes to the production of multiple cytokines in HNSCC. Because p38 MAPK can be constitutively active in HNSCC,15 the results of the current study suggest that inhibition of p38 MAPK in HNSCC would decrease cytokine secretion by preventing inactivation of TTP.

We also observed that TTP knockdown increased the secretion of multiple cytokines, but the effects on individual cytokines varied. This suggests that other pathways or multiple RNA-BPs are involved in the regulation of cytokines and the final effect on secretion may be determined by a balance among these factors. For example, TTP overexpression in mouse embryonic fibroblasts isolated from TTP knockout mice decreased VEGF but increased proliferation, whereas TTP overexpression in HeLa cells decreased cellular proliferation,12 suggesting that other proteins may influence proliferation in different cell types. These studies underscore the importance of delineating how cytokines are regulated in the context of a particular cell or tissue.

IL-6 is a pleiotropic cytokine that functions during inflammation, immunity, bone metabolism, neural development, reproduction, and hematopoiesis.46 Although epithelial malignancies may have elevated IL-6, to the best of our knowledge, the presence of tumor-derived IL-6 in HNSCC has not been investigated in the context of tumor progression.47 The identification of biomarkers that are prognostic of poor survival will allow for the selection of tumors for more aggressive treatment. The current study findings, derived from a small group of patients, suggest that HNSCCs with low TTP and high IL-6 expression have poorer DSS than HNSCCs with high TTP and low IL-6 expression. Similarly, in breast cancer, down-regulation of TTP is a negative prognostic indicator associated with increased tumor grade and mortality.12 However, TTP expression may not be the actual prognostic indicator in HNSCC. Our findings with IL-6, independent of TTP expression, support this theory. HNSCCs with high IL-6 expression have poor outcomes, including poor DSS, tumor recurrence, and the development of second primary tumors. Consistent with these observations, high serum IL-6 in HNSCC patients is correlated with poor overall survival and an increase in IL-6 during treatment is associated with tumor recurrence.37,48 Furthermore, high serum IL-6 is associated with resistance to radiotherapy.49

The results of the current study demonstrate that loss of TTP in HNSCC increases invasion and cell migration. Similarly, in breast cancer, invasion is decreased when TTP expression is re-established.45 The increased invasion and migration may be because of increased cytokine production or TTP may directly regulate proteins responsible for migration in HNSCC.42 TTP stabilizes multiple transcripts that affect invasion and tumor progression, including VEGF, COX-2, urokinase plasminogen activator, MMP-1, and IL-8.13,44,45,50

Given the importance of cytokines in invasion and proliferation, both of which contribute to HNSCC progression, disruption of cytokine secretion is an attractive treatment strategy. However, targeting cancers with a cocktail of inhibitors is impractical and, as mentioned earlier, targeting individual cytokines, such as monoclonal antibodies against IL-6 in patients with multiple myeloma, is ineffective in improving patient survival.36 Therefore, up-regulation of a protein, such as TTP, that inhibits multiple cytokines is an attractive treatment strategy, particularly if it can be combined with p38 inhibitors, because p38, which inactivates TTP, is constitutively active in HNSCC.15 However, because of the importance of cytokines in the immune response, the potential for systemic immunosuppression as a side effect of p38 inhibitors would be a challenge, particularly because it may promote tumor progression.51,52 This may be overcome by strategies that specifically target the treatment to tumor cells. Future studies will explore the mechanisms by which
TTP-mediated cytokine secretion regulates tumor progression and the feasibility of targeting this protein to control tumor growth.

CONFLICT OF INTEREST DISCLOSURES

Supported by National Institute of Dental and Craniofacial Research grants R01-DE018512, K02-DE019513, and R21-DE017977 (to N. J. D’Silva); National Cancer Institute: P50-CA97248 (University of Michigan Head and Neck SPORE); R01-DE018290 and 5R21 DE017966 (to K.L. Kirkwood); CA97248 (University of Michigan Head and Neck SPORE); Supported by National Institute of Dental and Craniofacial...

REFERENCES

3. Within the text, a reference is cited that is not visible in the provided image. Please check the full reference list for complete details.
the oral cavity and oropharynx. Recent Results Cancer Res. 1994;134:133-143.